Ptc Therapeutics INC (PTCT) Holder Great Point Partners LLC Has Upped Position

March 14, 2018 - By Linda Rogers

Investors sentiment increased to 1.71 in 2017 Q3. Its up 0.79, from 0.92 in 2017Q2. It is positive, as 13 investors sold PTCT shares while 28 reduced holdings. 25 funds opened positions while 45 raised stakes. 32.89 million shares or 5.85% more from 31.07 million shares in 2017Q2 were reported. Blackrock stated it has 3.14M shares. Usa Fincl Portformulas holds 0.11% or 23,214 shares. South Dakota Inv Council holds 157,800 shares or 0.06% of its portfolio. 329,097 are held by Ubs Asset Mngmt Americas. Credit Suisse Ag has invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). The New York-based Pinnacle has invested 0.12% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Tower Research Cap Ltd (Trc) owns 554 shares for 0% of their portfolio. Jane Street Group Ltd Liability owns 0.01% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 78,768 shares. Oppenheimer & Company Inc has invested 0.01% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Point72 Asset Mngmt LP holds 400,000 shares or 0.04% of its portfolio. Bogle Management Lp De reported 556,809 shares. Meeder Asset Mngmt reported 383 shares. Alliancebernstein L P, a New York-based fund reported 49,350 shares. Balyasny Asset reported 0% stake. Millennium Mgmt holds 0.01% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 260,633 shares.

Since January 3, 2018, it had 0 insider purchases, and 4 selling transactions for $61,523 activity. Utter Christine Marie sold $7,280 worth of stock or 412 shares. Another trade for 2,230 shares valued at $40,207 was sold by Peltz Stuart Walter.

Jeffrey Jay increased its stake in Ptc Therapeutics Inc (PTCT) by 323.08% based on its latest 2017Q3 regulatory filing with the SEC. Great Point Partners Llc bought 840,000 shares as the company’s stock declined 3.95% while stock markets rallied. The hedge fund run by Jeffrey Jay held 1.10 million shares of the health care company at the end of 2017Q3, valued at $22.01 million, up from 260,000 at the end of the previous reported quarter. Great Point Partners Llc who had been investing in Ptc Therapeutics Inc for a number of months, seems to be bullish on the $1.27B market cap company. The stock increased 1.67% or $0.5 during the last trading session, reaching $30.39. About 1.03 million shares traded or 10.34% up from the average. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 104.51% since March 14, 2017 and is uptrending. It has outperformed by 87.81% the S&P500.

Great Point Partners Llc, which manages about $935.83M and $514.03M US Long portfolio, decreased its stake in Arena Pharmaceuticals Inc by 1.08M shares to 1.36M shares, valued at $34.62 million in 2017Q3, according to the filing. It also reduced its holding in Zogenix Inc (Put) by 2.07M shares in the quarter, leaving it with 375,000 shares, and cut its stake in Adamas Pharmaceuticals Inc (NASDAQ:ADMS).

More important recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: which released: “PTC Therapeutics Receives Formal Dispute Resolution Request Decision from the …” on February 20, 2018, also published article titled: “Earnings Reaction History: PTC Therapeutics, Inc., 40.0% Follow-Through …”, published: “PTC Therapeutics Launches Fourth Annual STRIVE Grant Award Program for …” on February 13, 2018. More interesting news about PTC Therapeutics, Inc. (NASDAQ:PTCT) was released by: and their article: “PTC Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results …” with publication date: March 06, 2018.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage

Among 12 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 1 Sell and 7 Hold. Therefore 33% are positive. PTC Therapeutics had 38 analyst reports since July 31, 2015 according to SRatingsIntel. On Friday, June 30 the stock rating was maintained by Cowen & Co with “Hold”. The firm has “Outperform” rating given on Monday, November 14 by Credit Suisse. The rating was initiated by Jefferies with “Hold” on Friday, October 23. JP Morgan downgraded PTC Therapeutics, Inc. (NASDAQ:PTCT) on Monday, October 9 to “Underweight” rating. As per Tuesday, July 26, the company rating was downgraded by Credit Suisse. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Hold” rating by RBC Capital Markets on Wednesday, March 7. The firm has “Hold” rating given on Thursday, November 16 by J.P. Morgan. The firm earned “Outperform” rating on Wednesday, January 20 by Credit Suisse. As per Tuesday, August 25, the company rating was initiated by Citigroup. The firm has “Neutral” rating given on Thursday, November 16 by JP Morgan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.